NO2399993T3 - - Google Patents

Info

Publication number
NO2399993T3
NO2399993T3 NO10743584A NO10743584A NO2399993T3 NO 2399993 T3 NO2399993 T3 NO 2399993T3 NO 10743584 A NO10743584 A NO 10743584A NO 10743584 A NO10743584 A NO 10743584A NO 2399993 T3 NO2399993 T3 NO 2399993T3
Authority
NO
Norway
Application number
NO10743584A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2399993T3 publication Critical patent/NO2399993T3/no

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/14Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO10743584A 2009-02-20 2010-02-19 NO2399993T3 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009037750 2009-02-20
PCT/JP2010/001100 WO2010095455A1 (fr) 2009-02-20 2010-02-19 Streptavidine hypo-immunogène et son utilisation

Publications (1)

Publication Number Publication Date
NO2399993T3 true NO2399993T3 (fr) 2018-02-17

Family

ID=42633742

Family Applications (1)

Application Number Title Priority Date Filing Date
NO10743584A NO2399993T3 (fr) 2009-02-20 2010-02-19

Country Status (7)

Country Link
US (1) US8546537B2 (fr)
EP (1) EP2399993B1 (fr)
JP (1) JP5472754B2 (fr)
CN (1) CN102325884B (fr)
CA (1) CA2753048C (fr)
NO (1) NO2399993T3 (fr)
WO (1) WO2010095455A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105073770B (zh) * 2012-11-16 2019-08-06 Iba股份有限公司 链霉亲和素突变蛋白及其使用方法
JP6178586B2 (ja) * 2013-02-20 2017-08-09 サヴィッド・セラピューティックス株式会社 ビオチン改変体、ストレプトアビジン変異体およびそれらの利用
JP6096371B2 (ja) * 2014-02-18 2017-03-15 サヴィッド・セラピューティックス株式会社 ビオチン改変体、ストレプトアビジン変異体およびそれらの利用
WO2017050947A1 (fr) * 2015-09-23 2017-03-30 European Molecular Biology Laboratory Streptavidine résistant aux protéases
WO2018097239A1 (fr) 2016-11-25 2018-05-31 サヴィッド・セラピューティックス株式会社 Agent d'élimination
US20210214376A1 (en) 2018-05-30 2021-07-15 The University Of Tokyo Halogenated biotin-modified dimer and use thereof
JP7650459B2 (ja) 2020-04-14 2025-03-25 国立大学法人 東京大学 ビオチン改変二量体およびその利用
CN116916968A (zh) 2020-10-30 2023-10-20 托德·斯皮尔 基于寡核苷酸的治疗剂及其用途
CN117677701A (zh) 2021-07-29 2024-03-08 国立大学法人东京大学 抗原结合分子与链霉亲和素突变体的融合蛋白

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4135543A1 (de) 1991-10-28 1993-04-29 Boehringer Mannheim Gmbh Rekombinantes core-streptavidin
EP0646019B9 (fr) 1992-06-09 2002-12-18 Neorx Corporation Biotine-DOTA conjugués et leur utilisation dans des procédés de préciblage
US6022951A (en) 1995-04-11 2000-02-08 Univ Boston Streptavidin mutants
JP2001511007A (ja) * 1997-02-10 2001-08-07 カナダ国 低温誘発性甘味増加の減少を伴うαグルカンL−タイプまたはH−タイプ塊茎ホスホリラーゼのレベルの低下したトランスジェニックポテト
AU5597500A (en) * 1999-06-07 2000-12-28 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US20030143233A1 (en) 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US7148051B2 (en) * 2004-08-16 2006-12-12 E. I. Du Pont De Nemours And Company Production of 3-hydroxycarboxylic acid using nitrilase
JP5117765B2 (ja) 2007-05-28 2013-01-16 国立大学法人 東京大学 抗robo1抗体を含むpet用腫瘍診断剤

Also Published As

Publication number Publication date
JPWO2010095455A1 (ja) 2012-08-23
EP2399993A9 (fr) 2012-07-18
CA2753048A1 (fr) 2010-08-26
CN102325884A (zh) 2012-01-18
EP2399993A1 (fr) 2011-12-28
WO2010095455A1 (fr) 2010-08-26
EP2399993A4 (fr) 2013-07-03
US20120039879A1 (en) 2012-02-16
CN102325884B (zh) 2013-11-20
CA2753048C (fr) 2015-11-03
JP5472754B2 (ja) 2014-04-16
EP2399993B1 (fr) 2017-09-20
US8546537B2 (en) 2013-10-01

Similar Documents

Publication Publication Date Title
BRPI0925311A2 (fr)
BR112012008195A2 (fr)
BRPI0924307A2 (fr)
BR112012008267A2 (fr)
BR112012012396A2 (fr)
BR122021004633A2 (fr)
BR112012012487A2 (fr)
BR122017024704A2 (fr)
BR112012012080A2 (fr)
BRPI0924534A2 (fr)
BR112012009797A2 (fr)
BR112012009446A2 (fr)
BR112012009703A2 (fr)
BR112012010357A2 (fr)
BRPI1004942A2 (fr)
BR122019005883A2 (fr)
BR112012014856A2 (fr)
BR112012007672A2 (fr)
BR112012007671A2 (fr)
BR112012009404A2 (fr)
BRPI1014557A2 (fr)
BR122017013721A2 (fr)
BRPI0925022A2 (fr)
BRPI0924617A2 (fr)
BR112012016234A2 (fr)